In the July issue of Report on Progress titled, “Persistent Failure of ‘Disease-Modifying’ Drugs to Benefit Alzheimer Disease: Now What?” John C. Morris, M.D., discusses how the Baxter Phase III trial for intravenous immunoglobulin failed and Eli Lilly’s Phase II trial of a beta secretase inhibitor was stopped last month because certain factors caused toxic damage to the liver. He writes:
Such discouraging results unfortunately are not new to the AD field. Since 2001 there have been seven Phase III and two Phase II clinical trials in individuals with symptomatic AD of therapeutic agents that target amyloid-beta (Aβ). Aβ is a brain peptide that when dysregulated is believed by many investigators to be central to the pathogenesis of AD. All of these trials have failed due to either lack of efficacy, development of adverse events, or both. The continuing failure of these therapeutic agents understandably has produced reluctance in some investors to continue to underwrite the high costs involved in finding truly effective therapies for AD.
Morris goes on to give three factors as to why the drugs may not have worked. Click here for the full article and additional information.